Maxpro Capital (NASDAQ:JMAC) announced in an 8-K this morning that it has entered into a PIPE agreements adding $23.65 million to its combination with drug developer Apollomics.
Of these, $21.35 million was raised at $10 per share as “Series A preferred shares”. These will be convertible into 1.25 common shares each and will be locked up for six months. An additional $2.3 million PIPE was raised at $10 per share without these benefits, but these shares are to come with a 1/4 warrant attached that may be exercised between six months and five years out from close.
The parties originally announced their $932 million deal in September 2022. Foster City, California-based Apollomics is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets.
In November, it received an orphan drug designation for its APL-101 drug candidate, which is in Phase II trials to potentially treat non-small cell lung cancer and other cancer types.
Maxpro has a transaction deadline coming up on April 13 and it has already used its two automatic extensions.
Terms Tracker for the Week Ending February 14, 2025 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. It was another active week in the SPAC market, with four new SPACs filing to IPO and three new IPOs pricing—all of which managed to...
At the SPAC of Dawn Lost in the daily assault of A.I. company news are all of the “other” companies that were created in the past decade or so. The normies. These venture-backed companies that achieved unicorn status during the boom years of 2020 and 2021 have been sidelined and much has been discussed about...
Quantum computing has been one of the hottest investment topics in the past two months and three of the leading listed companies in the space are de-SPACs. But, how close is quantum computing to generating real value and what capabilities are still years away? This week, we speak with Alan Baratz, CEO of D–Wave (NYSE:QBTS), which...
At the SPAC of Dawn The sudden burst of SPAC activity this week slowed down after the closing bell yesterday as the market faces a period sandwiched between CPI and PPI readouts. Yesterday’s CPI news and Fed Chair Jerome Powell’s comments before Congress did not provide an instant relief in terms of clarity on a...
Maywood Acquisition Corp. (NASDAQ:MAYAU) announced the pricing of its $75 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “MAYAU”, Thursday, February 13, 2025. Maywood will have a broad search focus and will pursue an initial business combination in any industry or geographic location. The team is led...